JERSEY
CITY, N.J., June 21,
2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd.
announces the release of a market assessment report on the
"Global Non-Viral Transfection Reagents Market-
(Type of Non-Viral Transfection System (Non-Viral Transfection
Reagents, Electroporation-based Transfection Systems, Other
Non-Viral Transfection Systems), Area of Application (Clinical
Applications, Research Applications) By End User (Academic and
Research Institutions, Pharmaceutical Companies, Other End-Users)),
By Region, Trends, Industry Competition Analysis, Revenue and
Forecast To 2031."
According to the latest research by InsightAce Analytic, the
Global Non-Viral Transfection Reagents Market is valued at
US$ 649.1 Mn in 2023, and it is
expected to reach US$ 1,157.5 Mn by
2031, with a CAGR of 7.7% during the forecast period of
2024-2031.
Transfection, vital for introducing nucleic acids into cells,
relies historically on viral vectors but increasingly on non-viral
transfection reagents. These chemicals, devoid of viral components,
are pivotal in gene therapy, cell-based therapies, and vaccine
development due to their safety, ease of use, and adaptability.
Request for Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/2533
Lipid-based (e.g., lipofectamine), polymer-based (e.g.,
polyethyleneimine), and nanoparticle-based (e.g., lipid and
polymeric nanoparticles) reagents offer distinct advantages like
high transfection efficiency, stability, and controlled release
kinetics. Their applications span various fields, providing precise
control over gene expression and offering advantages such as
reduced immunogenicity and lower costs compared to viral
vectors.
Non-viral transfection reagents are versatile tools with
applications in gene therapy, cell-based therapies, vaccine
development, and personalized medicine. Compared to viral vectors,
they offer benefits like reduced immunogenicity, lower costs, and
improved safety. Their adaptability allows precise control over
transfection efficiency and gene expression levels, making them
appealing for tailored therapies in genetic disorders, cancers, and
infectious diseases.
List of Prominent Players in the Non-Viral Transfection
Reagents Market:
- Altogen Biosystems
- Bio-Rad Laboratories
- BEX
- BTX
- Celsion
- Genprex
- Inovio Pharmaceuticals
- MaxCyte
- MilliporeSigma
- Nepa Gene
- OZ Biosciences
- Thermo Fisher Scientific
Non-Viral Transfection Reagents Market Report Scope:
Report
Attribute
|
Specifications
|
Market Size Value In
2023
|
USD 649.1 Mn
|
Market Size Value In
2031
|
USD 1,157.5
Mn
|
Growth Rate
CAGR
|
CAGR of 7.7% from 2024
to 2031
|
Quantitative
Units
|
Representation of
revenue in US$ Bn and CAGR from 2024 to 2031
|
Historic
Year
|
2019 to 2023
|
Forecast
Year
|
2024-2031
|
Report
Coverage
|
The forecast of
revenue, the position of the company, the competitive market
structure, growth prospects, and trends
|
Segments
Covered
|
By Type of Non-Viral
Transfection System, By Area of Application, By End-user and By
Region
|
Regional
Scope
|
North America; Europe;
Asia Pacific; Latin America; Middle East & Africa
|
Order 180 Pages Full Report @
https://www.insightaceanalytic.com/buy-report/2533
Market Dynamics:
Drivers:
The landscape of gene, cell, and RNA therapies witnessed
remarkable growth in 2023, with over 100 approved treatments
worldwide and an additional 3,700 in clinical and preclinical
development stages. This surge in gene therapy applications, driven
by the increasing demand for precision medicine, highlights the
pivotal role of non-viral transfection reagents.
These reagents, characterized by their high safety profiles and
versatility, are crucial in facilitating gene therapy methods,
particularly in the context of advancing CRISPR-Cas9 technologies
and the rising adoption of mRNA-based therapeutics. As the market
continues to expand, non-viral transfection reagents emerge as
indispensable tools, enabling the safe and efficient delivery of
genetic material into target cells, thus driving innovation and
progress in the field of gene therapy and personalized
medicine.
Challenges:
While non-viral transfection reagents offer promising
alternatives to viral vectors in gene therapy and related fields,
they face several challenges. The development process can be costly
and labor-intensive, hindering smaller firms and research
teams.
Moreover, these reagents often have limited capacity for genetic
payloads, struggle with in vivo delivery, and exhibit lower
transfection efficiency compared to viral vectors. Additionally,
concerns regarding immune response, toxicity, scalability, and
standardization pose significant hurdles. Addressing these
challenges is essential to fully unlock the potential of non-viral
transfection methods in biomedical research and clinical
applications.
Regional Trends:
The Asia-Pacific region is
witnessing rapid expansion in the biotechnology and pharmaceutical
industries, fueled by significant investments in research and
development. This growth, particularly prominent in countries like
China, Japan, and South
Korea, is driving an increased demand for non-viral
transfection reagents. Investments in gene therapy and gene editing
technologies, coupled with the growing prevalence of genetic
disorders, are propelling the adoption of these reagents for
precise delivery of genetic material to target cells.
The region's dominance in the market is also driven by the
significant number of genetic disorders affecting newborn babies.
In China alone, approximately
200,000 newborn babies each year are affected by genetic disorders,
representing 22% of monogenic mutations globally. This high
incidence of genetic disorders has led to a growing demand for gene
therapy, which in turn drives the demand for non-viral transfection
reagents.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/2533
Recent Developments:
- In May 2024, MilliporeSigma, the
U.S. and Canada Life Science division of Merck KGaA, Darmstadt,
Germany, has finalized a deal to
acquire Mirus Bio for $600 million.
Mirus Bio, a subsidiary of Gamma Biosciences specializes in the
research and distribution of transfection reagents, including
TransIT-VirusGEN. These reagents are instrumental in the
manufacturing process of gene therapies based on viral vectors.
This acquisition underscores MilliporeSigma's commitment to
advancing innovation in the life sciences sector, particularly in
the critical field of gene therapy production.
- In August 2023, Altogen
Biosystems announced and launched a new targeted reagent that can
deliver biomolecules to the lungs, treating pulmonary diseases.
According to the announcement, the drug has safely and effectively
transported small molecules, DNA, RNA, and proteins to the
lungs.
Segmentation of Non-Viral Transfection Reagents
Market-
By Type of Non-Viral Transfection System
- Non-Viral Transfection Reagents
- Electroporation-based Transfection Systems
- Other Non-Viral Transfection Systems
By Area of Application
- Clinical Applications
- Research Applications
By End-User
- Academic and Research Institutions
- Pharmaceutical Companies
- Other End-Users
By Region-
North America-
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and
Africa
For More Customization @
https://www.insightaceanalytic.com/customisation/2533
Why should buy this report:
- To receive a comprehensive analysis of the prospects for global
Non-Viral Transfection Reagents market
- To receive industry overview and future trends of global
Non-Viral Transfection Reagents market
- To analyze the Non-Viral Transfection Reagents market drivers
and challenges
- To get information on the Non-Viral Transfection Reagents
market size value (US$ Mn) forecast till 2031
- Major Investments, Mergers & Acquisition in global
Non-Viral Transfection Reagents industry
Other Related Reports Published by InsightAce
Analytic:
Microbiology Reagents Market
In Vitro Diagnostic (IVD) Reagents Market
Genome Editing/Genome Engineering Market
DNA and Gene Cloning Services Market
About Us:
InsightAce Analytic is a market research and consulting firm
that enables clients to make strategic decisions. Our qualitative
and quantitative market intelligence solutions inform the need for
market and competitive intelligence to expand businesses. We help
clients gain competitive advantage by identifying untapped markets,
exploring new and competing technologies, segmenting potential
markets and repositioning products. Our expertise is in providing
syndicated and custom market intelligence reports with an in-depth
analysis with key market insights in a timely and cost-effective
manner.
Contact Us:
InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn:
https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Logo:
https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/non-viral-transfection-reagents-market-worth-usd-1-157-5-million-to-2031---exclusive-report-by-insightace-analytic-302178822.html
SOURCE InsightAce Analytic Pvt. Ltd